Press release
Venous Thromboembolism Clinical Trials 2024: EMA, PDMA, FDA Approvals, Medication, Therapies, Mechanism of Action, Route of Administration and Companies by DelveInsight
Venous Thromboembolism Clinical Trials
"Venous Thromboembolism Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Venous Thromboembolism Market.
The Venous Thromboembolism Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Request for Sample Report here @ https://www.delveinsight.com/report-store/venous-thromboembolism-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Some of the key takeaways from the Venous Thromboembolism Pipeline Report:
• Venous Thromboembolism Companies across the globe are diligently working toward developing novel Venous Thromboembolism treatment therapies with a considerable amount of success over the years.
• Venous Thromboembolism companies working in the treatment market are Quercis Pharma, Ono Pharmaceutical, Anthos Therapeutics, Bristol Myers Squibb, Yuhan Corporation, Supergene, Tasly Pharmaceutical, GlycoMimetics and others, are developing therapies for the Venous Thromboembolism treatment
• Emerging Venous Thromboembolism therapies such as Isoquercetin, Abelacimab, are expected to have a significant impact on the Venous Thromboembolism market in the coming years.
• In October 2024, Regeneron Pharmaceuticals announced a Master Protocol for a Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of REGN9933 and REGN7508, Monoclonal Antibodies Against Factor XI for Prevention of Venous Thromboembolism in Patients With a Peripherally Inserted Central Catheter (ROXI-CATH)
• On October 2024, Anthos Therapeutics, Inc announced a Multicenter, Randomized, Open-label, Blinded Endpoint Evaluation, Phase 3 Study Comparing the Effect of Abelacimab vs. Dalteparin on Venous Thromboembolism (VTE) Recurrence and Bleeding in Patients With GI/GU Associated VTE
Venous Thromboembolism Overview
Venous Thromboembolism (Venous Thromboembolism) encompasses two related conditions: deep vein thrombosis (DVT) and pulmonary embolism (PE). DVT occurs when a blood clot forms in deep veins, usually in the legs, causing swelling, pain, redness, and warmth in the affected area. If part of the clot dislodges and travels to the lungs, it can result in PE, a life-threatening condition characterized by chest pain, shortness of breath, rapid heart rate, and in severe cases, sudden death.
Venous Thromboembolism is a major global health concern and a leading cause of preventable hospital deaths. Risk factors include prolonged immobility (e.g., during surgery or travel), cancer, pregnancy, oral contraceptives, hormone replacement therapy, genetic clotting disorders, and advanced age. Lifestyle factors such as smoking and obesity also contribute to Venous Thromboembolism risk.
Venous Thromboembolism Diagnosis typically involves imaging techniques like ultrasound for DVT and CT pulmonary angiography for PE, along with D-dimer blood tests. Venous Thromboembolism Treatment focuses on anticoagulation therapy, using drugs such as heparin, warfarin, or direct oral anticoagulants (DOACs) to prevent clot growth and recurrence. Preventive measures, such as compression stockings, physical activity, and prophylactic anticoagulation in high-risk patients, are essential in reducing Venous Thromboembolism incidence and complications. Early recognition and management are crucial for favorable outcomes.
Get a Free Sample PDF Report to know more about Venous Thromboembolism Pipeline Therapeutic Assessment- https://www.delveinsight.com/sample-request/venous-thromboembolism-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Venous Thromboembolism Route of Administration
Venous Thromboembolism pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.
Venous Thromboembolism Molecule Type
Venous Thromboembolism Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
Venous Thromboembolism Pipeline Therapeutics Assessment
• Venous Thromboembolism Assessment by Product Type
• Venous Thromboembolism By Stage and Product Type
• Venous Thromboembolism Assessment by Route of Administration
• Venous Thromboembolism By Stage and Route of Administration
• Venous Thromboembolism Assessment by Molecule Type
• Venous Thromboembolism by Stage and Molecule Type
DelveInsight's Venous Thromboembolism Report covers around 10+ products under different phases of clinical development like-
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Further Venous Thromboembolism product details are provided in the report. Download the Venous Thromboembolism pipeline report to learn more about the emerging Venous Thromboembolism therapies- https://www.delveinsight.com/report-store/venous-thromboembolism-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Venous Thromboembolism Pipeline Analysis:
The Venous Thromboembolism pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Venous Thromboembolism with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Venous Thromboembolism Treatment.
• Venous Thromboembolism key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Venous Thromboembolism Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Venous Thromboembolism market.
Download Sample PDF Report to know more about Venous Thromboembolism drugs and therapies- https://www.delveinsight.com/sample-request/venous-thromboembolism-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Scope of Venous Thromboembolism Pipeline Drug Insight
• Coverage: Global
• Key Venous Thromboembolism Companies: Quercis Pharma, Ono Pharmaceutical, Anthos Therapeutics, Bristol Myers Squibb, Yuhan Corporation, Supergene, Tasly Pharmaceutical, GlycoMimetics and others.
• Key Venous Thromboembolism Therapies: Isoquercetin, Abelacimab, and others.
• Venous Thromboembolism Therapeutic Assessment: Venous Thromboembolism current marketed and Venous Thromboembolism emerging therapies
• Venous Thromboembolism Market Dynamics: Venous Thromboembolism market drivers and Venous Thromboembolism market barriers
Request for Sample PDF Report for Venous Thromboembolism Pipeline Assessment and clinical trials - https://www.delveinsight.com/sample-request/venous-thromboembolism-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Contents
1. Venous Thromboembolism Report Introduction
2. Venous Thromboembolism Executive Summary
3. Venous Thromboembolism Overview:
4. Venous Thromboembolism- Analytical Perspective In-depth Commercial Assessment
5. Venous Thromboembolism Pipeline Therapeutics
6. Venous Thromboembolism Late Stage Products (Phase II/III)
7. Venous Thromboembolism Mid Stage Products (Phase II)
8. Venous Thromboembolism Early Stage Products (Phase I)
9. Venous Thromboembolism Preclinical Stage Products
10. Venous Thromboembolism Therapeutics Assessment
11. Venous Thromboembolism Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Venous Thromboembolism Companies
14. Venous Thromboembolism Key Products
15. Venous Thromboembolism Unmet Needs
16 . Venous Thromboembolism Market Drivers and Barriers
17. Venous Thromboembolism Future Perspectives and Conclusion
18. Venous Thromboembolism Analyst Views
19. Appendix
20. About DelveInsight
Trending Reports:
• Wegener S Granulomatosis/granulomatosis With Polyangiitis Market: https://www.delveinsight.com/report-store/wegeners-granulomatosis-market
• West Syndrome Market: https://www.delveinsight.com/infographics/west-syndrome-market
• Calcinosis Cutis Market: https://www.delveinsight.com/report-store/calcinosis-cutis-market
• Healthcare Partner Identification Services: https://www.delveinsight.com/consulting/partner-identification-services
• Brain Cancer Market: https://www.delveinsight.com/infographics/brain-cancer-market
• Diabetic Neuropathy Market: https://www.delveinsight.com/report-store/diabetic-peripheral-neuropathy-market
• Bladder Pain Syndrome Market: https://www.delveinsight.com/report-store/interstitial-cystitis-market
• Prader-willi Syndrome Market: https://www.delveinsight.com/report-store/prader-willi-syndrome-market
• Gaucher Disease Market: https://www.delveinsight.com/report-store/gauchers-disease-market
• Head And Neck Cancer Market: https://www.delveinsight.com/report-store/head-and-neck-cancer-hnc-market
• Intracranial Pressure Monitoring Devices Market: https://www.delveinsight.com/report-store/intracranial-pressure-monitoring-devices-market
• Cardiac Biomarkers Testing Devices Market: https://www.delveinsight.com/report-store/cardiac-biomarkers-testing-devices-market
• Deep Vein Thrombosis Market: https://www.delveinsight.com/report-store/deep-vein-thrombosis-market
• Neurovascular Thrombectomy Devices Market: https://www.delveinsight.com/report-store/neurovascular-thrombectomy-devices-market
• Pediatric Obesity Market: https://www.delveinsight.com/report-store/pediatric-obesity-market
• Acute Pancreatitis Market: https://www.delveinsight.com/infographics/acute-pancreatitis-market
• Anal Cancer Market: https://www.delveinsight.com/report-store/anal-cancer-market
• Apheresis Market: https://www.delveinsight.com/report-store/apheresis-market
• Bacterial Skin Diseases Market: https://www.delveinsight.com/report-store/bacterial-skin-diseases-market
• Blood Glucose Monitoring Systems Market: https://www.delveinsight.com/report-store/blood-glucose-monitoring-systems-market
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Chronic Inflammatory Demyelinating Polyneuropathy Market: https://www.delveinsight.com/report-store/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market
• Chronic Obstructive Pulmonary Disease Market: https://www.delveinsight.com/report-store/chronic-obstructive-pulmonary-disease-copd-market
• Concussions Market Size: https://www.delveinsight.com/report-store/concussions-market
• Diffuse Large B-cell Lymphoma Market: https://www.delveinsight.com/report-store/diffuse-large-b-cell-lymphoma-market
• Dyspnea Market: https://www.delveinsight.com/report-store/dyspnea-market
• Hearing Implants Market: https://www.delveinsight.com/report-store/hearing-implants-market
• Abetalipoproteinemia Market: https://www.delveinsight.com/report-store/abetalipoproteinemia-market
• Acid Sphingomyelinase Deficiency Market: https://www.delveinsight.com/report-store/acid-sphingomyelinase-deficiency-asmd-market
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting/primary-research-services
Case study: https://www.delveinsight.com/case-study/esmo-conference-coverage
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Venous Thromboembolism Clinical Trials 2024: EMA, PDMA, FDA Approvals, Medication, Therapies, Mechanism of Action, Route of Administration and Companies by DelveInsight here
News-ID: 3768496 • Views: …
More Releases from DelveInsight Business Research
Autosomal Dominant Optic Atrophy Market Set for Robust Growth Through 2034, Driv …
The autosomal dominant optic atrophy treatment market is experiencing significant expansion, driven by increasing disease awareness, rising prevalence, and R&D in precision medicine from key pharmaceutical players, including PYC Therapeutics and Stoke Therapeutics, among others.
DelveInsight's "Autosomal Dominant Optic Atrophy - Market Insight, Epidemiology And Market Forecast - 2034" report delivers an in-depth understanding of the ADOA treatment market, historical and forecasted epidemiology, as well as market trends across the US,…
Severe Asthma Market Set for Robust Growth Through 2034, Driven by Breakthrough …
The severe asthma treatment market is experiencing robust expansion, driven by rising disease prevalence, improved diagnostic approaches, and breakthrough therapeutic developments from key pharmaceutical players, including AstraZeneca, GlaxoSmithKline, Amgen, Teva Pharmaceutical Industries, Novartis, Sanofi, Regeneron Pharmaceutical, Boehringer Ingelheim Pharmaceuticals, Kyorin Pharmaceutical, Pfizer, Chiesi Farmaceutici, AB Science, Avalo Therapeutics, and Theravance Biopharma, among others.
DelveInsight's "Severe Asthma Market Insights, Epidemiology, and Market Forecast-2034" report delivers a comprehensive understanding of the severe asthma…
Systemic Lupus Erythematosus Pipeline Heats Up as 120+ Companies Advance Cutting …
The systemic lupus erythematosus (SLE) treatment pipeline is experiencing unprecedented expansion, driven by increasing disease awareness, rising prevalence, and breakthrough therapies from key pharmaceutical players, including Biogen, Idorsia Pharmaceuticals, AbbVie, BioSenic, Roche, Novartis, Allogene Therapeutics, Adicet Bio, and numerous other leading companies advancing innovative treatments through robust clinical development programs.
DelveInsight's "Systemic Lupus Erythematosus Pipeline Insight, 2025" report delivers comprehensive insights about 120+ companies and 140+ pipeline drugs currently in the…
Global Tumor Ablation Market to reach USD 4,595.68 million by 2032 at a CAGR of …
According to DelveInsight's analysis, The global Tumor Ablations (EHR) market is experiencing significant growth, driven by the increasing prevalence of chronic diseases that require continuous monitoring, data management, and coordinated long-term care. This demand has fueled the need for integrated healthcare systems capable of connecting patient information across multiple departments and care settings. To support this trend, governments worldwide are introducing initiatives, funding, mandates, and regulatory frameworks to promote EHR…
More Releases for Venous
States Venous Stents Market Projected to Witness Expansion with Rising Incidence …
States Venous Stents Market Overview
The States Venous Stents Market is expected to grow from USD 1.3 billion in 2025 to USD 2.4 billion by 2032, registering a CAGR of 8.9%.
Coherent Market Insights is pleased to release its latest States Venous Stents Market research report, offering an in-depth analysis of the U.S. States Venous Stents Market Landscape from 2025 to 2032. This report delivers reliable projections across national and regional levels,…
Venous Stent Market Grows with Rising Cases of Chronic Venous Disorders | Boston …
Venous Stent Market Overview
The venous stent market is anticipated to grow from USD 0.6 billion in 2025 to USD 1.3 billion by 2032, exhibiting a CAGR of 10.3% during the forecast period.
Coherent Market Insights is proud to announce the release of its latest market research report, providing a comprehensive analysis of the Venous Stent Market Landscape from 2025 to 2032. This report delivers precise forecasts across global, regional, and country…
Major Force in the Venous Thromboembolism Market 2025: Impact Of Healthcare Infr …
How Will the Venous Thromboembolism Market Grow, and What Is the Projected Market Size?
Over the past few years, the venous thromboembolism market has experienced a steady increase in its size. It's projected to expand from $2.44 billion in 2024 to $2.55 billion in 2025, rising at a compound annual growth rate (CAGR) of 4.4%. The growth during the historic period can be credited to an increasing elderly population, progress in…
Venous Catheter Market Size 2024 to 2031.
Market Overview and Report Coverage
A venous catheter is a small, flexible tube inserted into a vein for medical purposes such as accessing the bloodstream for medications, fluids, or blood sampling. The venous catheter market is expected to witness significant growth in the coming years, with a projected CAGR of 6.30% during the forecasted period.
The current outlook for the venous catheter market is positive, driven by factors such as…
Venous Skin Ulcer Treatment Market : Lucrative Opportunities
Venous Skin Ulcer Treatment Market: Introduction
According to the report, the global venous skin ulcer treatment market was valued at US$ 2.6 Bn in 2019. It is expected to expand at a CAGR of ~5% during the forecast period from 2020 to 2030. Various advanced technologies and treatment options are presently available for venous skin ulcer. The treatment for skin ulcer include different therapies such as compression therapy, advanced wound dressings,…
Increasing Prevalence of Venous Thromboembolism to Augment Growth of the Venous …
Venous thromboembolism (VTE) is the formation of blood clots in the bloodstream. Two main types of venous thromboembolism are pulmonary embolism and deep vein thrombosis. The formation of blood clots in a deep vein is called deep vein thrombosis, while the deep vein thrombosis formed breaks the clot and travels to the lungs, known as pulmonary embolism.
Sample Copy Of Report @ https://www.coherentmarketinsights.com/insight/request-sample/188
Pulmonary embolism occurs in almost one-third of patients…
